Europe Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2029
The Europe Motion Sickness Treatment Market would witness market growth of 3.0% CAGR during the forecast period (2023-2029).
The motion sickness treatment market is experiencing growth due to various factors, including a rise in the occurrence of motion sickness, an increase in demand for efficient treatments, and an upsurge in research and development efforts in the pharmaceutical industry. The pharmaceutical industry is experiencing growth and innovation in manufacturing motion sickness medications. This is due to the large population that experiences motion sickness, which presents a significant opportunity for market growth.
In recent years, there has been an increase in the number of approved products for motion sickness medication. The rise in the adoption of medications, including transdermal patches and other drugs, can be attributed to the approvals granted for both generic and branded versions. This drives the expansion of the market. Moreover, the increase in consumer knowledge regarding preventative healthcare and the convenience of accessing medications drives the uptake of motion sickness medications. Furthermore, the manufacturers' boost in promotional activities for new products is anticipated to drive their adoption throughout the projected period.
The United Kingdom's over-the-counter (OTC) drugs sector is expected to experience growth in the next few years due to increasing investments and expenses in pharmaceutical products and therapeutics. The UK's OTC drugs industry is expected to experience growth in the coming years due to increased government investment in the pharmaceutical industry and rising consumer demand for advanced and affordable pharmaceutical products. This investment is aimed at promoting local manufacturers and boosting the overall economy. Hence, with the growing adoption of OTC drugs to counter minor health issues to save cost and time for the user, the utilization of OTC-based drugs like antihistamines and anticholinergics will also increase to treat motion sickness and therefore drive the market expansion in Europe.
The Germany market dominated the Europe Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $33.1 Million by 2029. The UK market is estimated to grow at a CAGR of 2.2% during (2023 - 2029). Additionally, The France market would register a CAGR of 3.8% during (2023 - 2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Scope of the Study
Market Segments covered in the Report:
By Drug Class
Antihistamines
Anticholinergics
Others
By Route of Administration
Oral
Others
By Distribution Channel
Drug Store & Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Country
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Companies Profiled
Viatris, Inc.
Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals, Inc.
Baxter International, Inc.
Novartis AG
Abbott Laboratories
Sun Pharmaceutical Industries Ltd.
Zydus Lifesciences Ltd.
Prestige Consumer Healthcare, Inc.
WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Unique Offerings from KBV Research
Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Europe Motion Sickness Treatment Market, by Drug Class
- 1.4.2 Europe Motion Sickness Treatment Market, by Route of Administration
- 1.4.3 Europe Motion Sickness Treatment Market, by Distribution Channel
- 1.4.4 Europe Motion Sickness Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Europe Motion Sickness Treatment Market by Drug Class
- 3.1 Europe Antihistamines Market by Country
- 3.2 Europe Anticholinergics Market by Country
- 3.3 Europe Others Market by Country
- Chapter 4. Europe Motion Sickness Treatment Market by Route of Administration
- 4.1 Europe Oral Market by Country
- 4.2 Europe Others Market by Country
- Chapter 5. Europe Motion Sickness Treatment Market by Distribution Channel
- 5.1 Europe Drug Store & Retail Pharmacies Market by Country
- 5.2 Europe Hospital Pharmacies Market by Country
- 5.3 Europe Online Pharmacies Market by Country
- Chapter 6. Europe Motion Sickness Treatment Market by Country
- 6.1 Germany Motion Sickness Treatment Market
- 6.1.1 Germany Motion Sickness Treatment Market by Drug Class
- 6.1.2 Germany Motion Sickness Treatment Market by Route of Administration
- 6.1.3 Germany Motion Sickness Treatment Market by Distribution Channel
- 6.2 UK Motion Sickness Treatment Market
- 6.2.1 UK Motion Sickness Treatment Market by Drug Class
- 6.2.2 UK Motion Sickness Treatment Market by Route of Administration
- 6.2.3 UK Motion Sickness Treatment Market by Distribution Channel
- 6.3 France Motion Sickness Treatment Market
- 6.3.1 France Motion Sickness Treatment Market by Drug Class
- 6.3.2 France Motion Sickness Treatment Market by Route of Administration
- 6.3.3 France Motion Sickness Treatment Market by Distribution Channel
- 6.4 Russia Motion Sickness Treatment Market
- 6.4.1 Russia Motion Sickness Treatment Market by Drug Class
- 6.4.2 Russia Motion Sickness Treatment Market by Route of Administration
- 6.4.3 Russia Motion Sickness Treatment Market by Distribution Channel
- 6.5 Spain Motion Sickness Treatment Market
- 6.5.1 Spain Motion Sickness Treatment Market by Drug Class
- 6.5.2 Spain Motion Sickness Treatment Market by Route of Administration
- 6.5.3 Spain Motion Sickness Treatment Market by Distribution Channel
- 6.6 Italy Motion Sickness Treatment Market
- 6.6.1 Italy Motion Sickness Treatment Market by Drug Class
- 6.6.2 Italy Motion Sickness Treatment Market by Route of Administration
- 6.6.3 Italy Motion Sickness Treatment Market by Distribution Channel
- 6.7 Rest of Europe Motion Sickness Treatment Market
- 6.7.1 Rest of Europe Motion Sickness Treatment Market by Drug Class
- 6.7.2 Rest of Europe Motion Sickness Treatment Market by Route of Administration
- 6.7.3 Rest of Europe Motion Sickness Treatment Market by Distribution Channel
- Chapter 7. Company Profiles
- 7.1 Viatris, Inc.
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental Analysis
- 7.1.4 Research & Development Expense
- 7.2 Teva Pharmaceutical Industries Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional Analysis
- 7.2.4 Research & Development Expenses
- 7.3 Amneal Pharmaceuticals, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Segmental Analysis
- 7.3.4 Research & Development Expenses
- 7.4 Baxter International, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Segmental Analysis
- 7.4.4 Research & Development Expense
- 7.5 Novartis AG
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Segmental and Regional Analysis
- 7.5.4 Research & Development Expense
- 7.6 Abbott Laboratories
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Segmental and Regional Analysis
- 7.6.4 Research & Development Expense
- 7.6.5 SWOT Analysis
- 7.7 Sun Pharmaceutical Industries Ltd.
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Regional Analysis
- 7.7.4 Research & Development Expenses
- 7.8 Zydus Lifesciences Ltd.
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.8.5 Recent strategies and developments:
- 7.8.5.1 Trials and Approvals:
- 7.9 Prestige Consumer Healthcare, Inc.
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Segmental and Regional Analysis
- 7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
- 7.10.1 Company Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook